Combination of PD‐1/PD‐L1 checkpoint inhibition and dendritic cell therapy in mice models and in patients with mesothelioma

Immunotherapy with anti‐PD1/PD‐L1 is effective in only a subgroup of patients with malignant pleural mesothelioma (MPM). We investigated the efficacy of a combination of anti‐PD1/PD‐L1 and dendritic cell (DC) therapy to optimally induce effective anti‐tumor immunity in MPM in both humans and mice. D...

Descripción completa

Detalles Bibliográficos
Autores principales: van Gulijk, Mandy, Belderbos, Bob, Dumoulin, Daphne, Cornelissen, Robin, Bezemer, Koen, Klaase, Larissa, Dammeijer, Floris, Aerts, Joachim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
CANCER THERAPY AND PREVENTION
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092125/
https://www.ncbi.nlm.nih.gov/pubmed/36104949
http://dx.doi.org/10.1002/ijc.34293

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092125/
https://www.ncbi.nlm.nih.gov/pubmed/36104949
http://dx.doi.org/10.1002/ijc.34293

Ejemplares similares